Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab.
Fairley
Janet A
JA
Baum
Christian L
CL
Brandt
Debra S
DS
Messingham
Kelly A N
KA
D000368:Aged; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001323:Autoantibodies / Q000097:blood / Q000276:immunology*; D001324:Autoantigens / Q000276:immunology / Q000378:metabolism; D015551:Autoimmunity / Q000276:immunology*; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood / Q000276:immunology*; D024041:Non-Fibrillar Collagens / Q000276:immunology / Q000378:metabolism; D000069444:Omalizumab; D010391:Pemphigoid, Bullous / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D000097805:Collagen Type XVII
D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001323:Autoantibodies; D001324:Autoantigens; D007073:Immunoglobulin E; D024041:Non-Fibrillar Collagens; D000069444:Omalizumab; D000097805:Collagen Type XVII